Use of Topical Metronidazole in Moderate to Severe Rosacea

Advances in Therapy

Volumn 20, Issue 4, 2003, Pages 177-190

  Lowe, Nicholas J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Metronidazole; Oral antibiotic; Rosacea

Indexed keywords

ANTIBIOTIC AGENT; DOXYCYCLINE FOSFATEX; ERYTHROMYCIN; METROLOTION; METRONIDAZOLE; NORITRATE; OXYTETRACYCLINE; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DIET RESTRICTION; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FOLLOW UP; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MINIMUM INHIBITORY CONCENTRATION; PAPULE; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PHOTOSENSITIVITY DISORDER; PUSTULE; REMISSION; ROSACEA; SKIN ABSORPTION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; VAGINA CANDIDIASIS;

EID: 0345688216     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02850088     Document Type: Article

References (20)

1. Del Rosso JQ. A status report on the medical management of rosacea: focus on topical therapies. Cutis. 2002;70:271-275.
2. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46:584-587.
3. Rebora A. Rosacea. J Invest Dermatol. 1987;88(suppl 3):56S-60S.
4. Marks R, Harcourt-Webster JN. Histopathology of rosacea. Arch Dermatol. 1969;100:683-691.
5. Miyachi Y. Potential antioxidant mechanism of action for metronidazole: implications for rosacea management. Adv Ther. 2001;18:237-243.
6. Katz AM. Rosacea: epidemiology and pathogenesis. J Cutan Med Surg. 1998;2(suppl 4):S4-5-S4-9.
7. Wilkin JK. Rosacea. Pathophysiology and treatment. Arch Dermatol. 1994;130:359-362.
8. Miyachi Y. Pharmacologic modulation of neutrophil function. Clin Dermatol. 2000;18:369-373.
9. Bikowski JB. Rosacea: a tiered approach to therapy. Cutis. 2000;66(suppl 4):3-6.
10. Sneddon IB. A clinical trial of tetracycline in rosacea. Br J Dermatol. 1966;78:649-652.
11. Knight AG, Vickers CFH. A follow-up of tetracycline-treated rosacea. Br J Dermatol. 1975;93:577-580.
12. Nielsen PG. A double-blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. Br J Dermatol. 1983;109:63-65.
13. Nielsen PG. Treatment of rosacea with 1% metronidazole cream. A double-blind study. Br J Dermatol. 1983;108:327-332.
14. Aronson IK, Rumsfield JA, West DP, Alexander J, Fischer JH, Paloucek FP. Evaluation of topical metronidazole gel in acne rosacea. Drug Intell Clin Pharm. 1987;21:346-351.
15. Bleicher PA, Charles JH, Sober AJ. Topical metronidazole therapy for rosacea. Arch Dermatol. 1987;123:609-614.
16. Lowe NJ, Henderson T, Millikan LE, Smith S, Turk K, Parker F. Topical metronidazole for severe and recalcitrant rosacea: a prospective open trial. Cutis. 1989;43:283-286.
17. Dahl MV, Jarratt M, Kaplan D, et al. Once-daily topical metronidazole cream formulations in the treatment of the papules and pustules of rosacea. J Am Acad Dermatol. 2001;45:723-730.
18. Jorizzo JL, Lebwohl M, Tobey RE. The efficacy of metronidazole 1% cream once daily compared with metronidazole 1% cream twice daily and their vehicles in rosacea: a double-blind clinical trial. J Am Acad Dermatol. 1998;39:502-504.
19. Wagner N, Berthaud C, Laffet G, Caron JC. Differential penetration of skin by topical metronidazole formulations. Adv Ther. 1998;15:197-205.
20. Dahl MV, Katz I, Krueger GG, et al. Topical metronidazole maintains remissions of rosacea. Arch Dermatol. 1998;134:679-683.